CERECOR INC. (NASDAQ:CERC) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

CERECOR INC. (NASDAQ:CERC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01EntryintoaMaterialDefinitiveAgreement.

As previously disclosed in the Current Report on Form8-K filed by Cerecor Inc. (the “Company”) on February12, 2018, the Company entered into a licensing and development agreement with Flamel Ireland Limited (“Avadel Ireland”), a subsidiary of Avadel US Holdings,Inc., dated February16, 2018 (the “Development Agreement”).

A description of the Development Agreement is included in Item 1.01 of the Current Report on Form8-K filed by the Company on February12, 2018, and such description is incorporated into this Item 1.01 by reference.

Item 2.01. Completion of Acquisition or Disposition of Assets.

On February16, 2018, the Company closed its previously disclosed acquisition (the “Transaction”) of certain pediatric products of Avadel US Holdings,Inc., Avadel Pharmaceuticals (USA),Inc., Avadel Pediatrics,Inc., Avadel Therapeutics, LLC and Avadel Pharmaceuticals PLC. For more information on the Transaction and the Asset Purchase Agreement associated with the Transaction, see the Form8-K the Company filed on February12, 2018, which is incorporated into this Item 2.01 by reference.

Item 9.01. Financial Statements and Exhibits.

a) Financial Statements of Businesses Acquired.

To the extent required, the Company intends to file the financial statements required by Item 9.01(a)as part of an amendment to this Current Report on Form8-K no later than 71 calendar days after the required filing date for this Current Report on Form8-K.

(b)Pro Forma Financial Information.

To the extent required, the Company intends to file the pro forma financial information required by Item 9.01(b)as an amendment to this Current Report on Form8-K no later than 71 days after the required filing date for this Current Report on Form8-K.


About CERECOR INC. (NASDAQ:CERC)

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.